Lenvatinib-d4 is a deuterium substitute of Lenvatinib. Lenvatinib is an orally active, multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor (PDGFR), Stem cell factor receptor (KIT) and intertransfection rearrangement (RET).
- Size: 1mg
- Purity: ≥98%
- Brand: Saint Michael
- Catalogue No.: ILA1808-1mg
For laboratory research use only. Not for human or animal consumption, diagnostic or therapeutic use.
Write Your Own Review